All Stories

  1. RAB32 mutation in Parkinson's disease
  2. Dystonic Tremor as Main Clinical Manifestation of SCA21
  3. Neurosteroid Levels in GBA Mutated and Non-Mutated Parkinson’s Disease: A Possible Factor Influencing Clinical Phenotype?
  4. Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?
  5. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease
  6. The p.Val234Met LRP10 likely pathogenic variant associated with Parkinson's disease: Possible molecular implications
  7. Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson’s Disease: A Retrospective Study by Different Expert Centers
  8. Soft cerebellar signs unveil RARS2‐related epilepsy
  9. A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With Dystonia-Parkinsonism
  10. Unleashing the potential of mRNA therapeutics for inherited neurological diseases
  11. Comparing Essential Tremor with and without Soft Dystonic Signs and Tremor Combined with Dystonia: The TITAN Study
  12. Genotype–phenotype correlation in PRKN-associated Parkinson’s disease
  13. A Novel Pathogenic PSEN1 Variant in a Patient With Dystonia-Parkinsonism Without Dementia
  14. Genetics in Parkinson’s disease, state-of-the-art and future perspectives
  15. Dominant VPS16 Pathogenic Variants: Not Only Isolated Dystonia
  16. Are patients with GBA–Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort
  17. Speech, Gait, and Vestibular Function in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome
  18. Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study
  19. Editorial: Genetic advances and translational applications in movement disorders
  20. Clinical correlates of “pure” essential tremor: the TITAN study
  21. GABRB1‐related early onset developmental and epileptic encephalopathy: Clinical trajectory and novel de novo mutation
  22. Chorea‐Acanthocytosis Presenting with Parkinsonism‐Dystonia without Chorea
  23. Levodopa responsive asymmetric parkinsonism as clinical presentation of progranulin gene mutation.
  24. Dystonia Linked to EIF4A2 Haploinsufficiency: A Disorder of Protein Translation Dysfunction
  25. Don’t forget Allgrove syndrome in adult patients as a bulbar-ALS mimicker
  26. The unexpected finding of CNS autoantibodies in GBA1 mutation carriers with atypical parkinsonism
  27. A form of inherited hyperferritinemia associated with bi-allelic pathogenic variants of STAB1
  28. SCARB1 downregulation in adrenal insufficiency with Allgrove syndrome
  29. Kufor Rakeb syndrome without gaze palsy and pyramidal signs due to novel ATP13A2 mutations
  30. Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation
  31. Reply to: “Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort”
  32. Genetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview
  33. Whole-Exome Sequencing Study of Fibroblasts Derived From Patients With Cerebellar Ataxia Referred to Investigate CoQ10 Deficiency
  34. Deconstructing speech alterations in episodic ataxia type 2: Perceptual-acoustic analysis in a case due to CACNA1A gene mutation
  35. Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
  36. Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
  37. iPSC-Derived Striatal Medium Spiny Neurons from Patients with Multiple System Atrophy Show Hypoexcitability and Elevated α-Synuclein Release
  38. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms
  39. Tremulous spastic ataxia in a patient with a homozygous truncating SYNE1 variant
  40. Verbal Learning Impairment in Parkinson’s Disease: Role of the Frontostriatal System in Working and Strategic Memory
  41. Early-onset inherited dystonias versus late-onset idiopathic dystonias: Same or different biological mechanisms?
  42. Two cases of Huntington’s disease unmasked by the COVID-19 pandemic
  43. A sensitive method for determining UDP-glucose: ceramide glucosyltransferase (UGCG) activity in biological samples using deuterated glucosylceramide as acceptor substrate
  44. Anderson–Fabry Disease: A New Piece of the Lysosomal Puzzle in Parkinson Disease?
  45. BiallelicSTAB1pathogenic variants cause hereditary hyperferritinemia
  46. Nuclear Pore Complex Dysfunction in Dystonia Pathogenesis: Nucleoporins in the Spotlight
  47. Approaching the Gut and Nasal Microbiota in Parkinson’s Disease in the Era of the Seed Amplification Assays
  48. SCARB1 downregulation in adrenal insufficiency with Allgrove Syndrome
  49. Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts
  50. Adult-onset KMT2B-related dystonia
  51. A Bayesian approach to Essential Tremor plus: A preliminary analysis of the TITAN cohort
  52. Juvenile-onset dystonia with spasticity in Leigh syndrome caused by a novel NDUFA10 variant
  53. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease
  54. Trial of Cinpanemab in Early Parkinson’s Disease
  55. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration
  56. Changes in non-motor symptoms in patients with Parkinson's disease following COVID-19 pandemic restrictions: A systematic review
  57. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease
  58. Case Report: Effect of Targeted Therapy With Carbamazepine in KCNQ2 Neonatal Epilepsy
  59. TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study
  60. The apparent paradox of phenotypic diversity and shared mechanisms across dystonia syndromes
  61. Axial improvement after casirivimab/imdevimab treatment for COVID-19 in Parkinson Disease
  62. Correction to: The Italian tremor Network (TITAN): rationale, design and preliminary findings
  63. Cognitive and Autonomic Dysfunction in Multiple System Atrophy Type P and C: A Comparative Study
  64. Genetic evaluation in phenotypically discordant monozygotic twins with Coats Disease
  65. The Italian tremor Network (TITAN): rationale, design and preliminary findings
  66. Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review
  67. Progressive myoclonus without epilepsy due to a NUS1 frameshift insertion: Dyssynergia cerebellaris myoclonica revisited
  68. Dysautonomia in Parkinson’s Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control
  69. Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia
  70. Role of Lysosomal Gene Variants in Modulating GBA ‐Associated Parkinson's Disease Risk
  71. A Practical Approach to Early-Onset Parkinsonism
  72. Freezing of gait: overview on etiology, treatment, and future directions
  73. VPS13C-associated Parkinson's disease: Two novel cases and review of the literature
  74. Transcriptome deregulation of peripheral monocytes in GBA-related Parkinson’s disease
  75. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
  76. Parkinsonism and ataxia
  77. The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson’s disease
  78. A 79-year-old man with unexplained recurrent syncope and severe orthostatic hypotension
  79. Sodium Levels Predict Disability at Discharge in Guillain-Barré Syndrome: A Retrospective Cohort Study
  80. Screening of LRP10 mutations in Parkinson's disease patients from Italy
  81. Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia
  82. HOPS-associated neurological disorders (HOPSANDs): linking endolysosomal dysfunction to the pathogenesis of dystonia
  83. Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis
  84. Targeting the Autonomic Nervous System for Risk Stratification, Outcome Prediction and Neuromodulation in Ischemic Stroke
  85. Clinical features and disease course of patients with acute ischaemic stroke just before the Italian index case: Was COVID-19 already there?
  86. A novel homozygous VPS11 variant may cause generalized dystonia
  87. Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review
  88. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  89. Expanding the genotypic and phenotypic spectrum of Beta‐propeller potein‐associated neurodegeneration
  90. A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation
  91. A rapid and low-cost test for screening the most common Parkinson's disease-related GBA variants
  92. Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity
  93. The SPID-GBA study
  94. Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum
  95. Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
  96. Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies
  97. GBA ‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort
  98. Late-onset leukoencephalopathy in a patient with recessive EARS2 mutations
  99. Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration
  100. Design and Operation of the Lombardy Parkinson's Disease Network
  101. Pharmacological Antagonism of Kainate Receptor Rescues Dysfunction and Loss of Dopamine Neurons in a Mouse Model of Human Parkin-induced Toxicity 
  102. The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease
  103. Systemic involvement in adult‐onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome) with a novel mutation of SNORD118 gene
  104. SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy
  105. Microscopic Polyangiitis With Selective Involvement of Central and Peripheral Nervous System: A Case Report
  106. Dystonia‐ataxia syndrome with permanent torsional nystagmus caused by ECHS1 deficiency
  107. Childhood onset dystonia with cerebellar signs: expanding the spectrum of GNAL mutations
  108. Loss of the nucleoporin Aladin in central nervous system and fibroblasts of Allgrove Syndrome
  109. Validation of the Italian version of the PSP Quality of Life questionnaire
  110. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives
  111. Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy
  112. Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy
  113. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
  114. Parkinsonism in diseases predominantly presenting with dystonia
  115. Spinal direct current stimulation (tsDCS) in hereditary spastic paraplegias (HSP): A sham-controlled crossover study
  116. Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy
  117. Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy
  118. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study
  119. Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?
  120. Syncope and autonomic failure in a middle-aged man
  121. The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson’s Disease
  122. Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss
  123. In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells
  124. A de novo C19orf12 heterozygous mutation in a patient with MPAN
  125. Real life evaluation of safinamide effectiveness in Parkinson’s disease
  126. X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene
  127. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p
  128. Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin’s Lymphoma: A Case Report
  129. Mutations in TMEM230 are rare in autosomal dominant Parkinson's disease
  130. Globus pallidus internus deep brain stimulation in PINK-1 related Parkinson's disease: A case report
  131. Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients
  132. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease
  133. Mutational analysis of COQ2 in patients with MSA in Italy
  134. Autophagy in motor neuron disease: Key pathogenetic mechanisms and therapeutic targets
  135. Abnormal brain temperature in early-onset Parkinson's disease
  136. Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson’s Disease
  137. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation
  138. Designing geographical indication institutions when stakeholders’ incentives are not perfectly aligned
  139. Adaptive deep brain stimulation in patients with Parkinson’s disease: phase II clinical trial preliminary results
  140. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis
  141. Adaptive deep brain stimulation in a freely moving parkinsonian patient
  142. A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism
  143. Cerebellar tDCS: How to Do It
  144. Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation
  145. Biochemical markers in early diagnosis and management of systemic amyloidoses
  146. Obesity and Headache/Migraine: The Importance of Weight Reduction through Lifestyle Modifications
  147. Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism
  148. Mutations in DNA2 Link Progressive Myopathy to Mitochondrial DNA Instability
  149. Congenital Myasthenic Syndrome Due to Choline Acetyltransferase Mutations in Infants
  150. The novel mitochondrial tRNAAsn gene mutation m.5709T>C produces ophthalmoparesis and respiratory impairment
  151. Two novel mutations in PEO1 (Twinkle) gene associated with chronic external ophthalmoplegia
  152. Unusual adult-onset Leigh syndrome presentation due to the mitochondrial m.9176T>C mutation
  153. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
  154. Autosomal dominant restless legs syndrome maps to chromosome 20p13 (RLS-5) in a Dutch kindred
  155. GIGYF2 mutations are not a frequent cause of familial Parkinson's disease
  156. The Mitochondrial Disulfide Relay System Protein GFER Is Mutated in Autosomal-Recessive Myopathy with Cataract and Combined Respiratory-Chain Deficiency
  157. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome
  158. Pseudo-orthostatic and resting leg tremor in a large spanish family with homozygous truncating parkin mutation
  159. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population
  160. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
  161. LRRK2 MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8
  162. SPG11: a consistent clinical phenotype in a family with homozygous Spatacsin truncating mutation
  163. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
  164. Parkin polymorphisms and environmental exposure: Decrease in age at onset of Parkinson's disease
  165. LRRK2 mutations and Parkinson's disease in Sardinia—A Mediterranean genetic isolate
  166. High prevalence ofLRRK2 mutations in familial and sporadic Parkinson's disease in Portugal
  167. Neuropathology of Parkinson's disease associated with theLRRK2 Ile1371Val mutation
  168. 1.283 Clinical and genetic study of a large Dutch family with autosomal dominant restless legs syndrome
  169. 2.119 Parkin polymorphisms and environmental exposure: Reduction of Parkinson's disease age of onset
  170. LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample
  171. The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence
  172. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan
  173. Striatal dopamine transporter binding in Parkinson's disease associated with theLRRK2 Gly2019Ser mutation
  174. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
  175. A case of CPT deficiency, homoplasmic mtDNA mutation and ragged red fibers at muscle biopsy
  176. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease
  177. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor
  178. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease
  179. POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions
  180. Remarkable infidelity of polymerase  A associated with mutations in POLG1 exonuclease domain
  181. Novel missense mutation and large deletion ofGNE gene in autosomal-recessive inclusion-body myopathy